NCT01747577已完成4 期
A Randomized, Double-blind, Placebo-controlled, Parallel-group, and Phase IV Study of Efficacy and Safety of Solifenacin Succinate in Patients With Overactive Bladder After TURP or PVP
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 68
- 主要终点
- Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 2
研究概览
简要总结
The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.
详细描述
The BPH (benign prostate hyperplasia) patients who have OAB (overactive bladder) after TURP (trans-urethral resection of prostate) or PVP (photoselective vaporization of prostate) will participate in this study. The subjects will be randomized 1:1 to the solifenacin succinate group or to the placebo treatment group. The subjects shall take investigational product each night before sleeping from for four weeks and complete voiding diary. At Week-2 and Week-4 of the treatment, the subjects will be asked to complete the following activities: physical exam, vital signs test, IPSS, OABSS, post-void residual (PVR) test, and uroflowmetry, and will be asked to answer the BSW, (Benefit, Satisfaction and Willingness to Continue Questions) questionnaire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Screening
- •Patients who are willing and able to accurately complete the voiding diary, IPSS, and OABSS
- •Patients who have been diagnosed with BPH and are scheduled to receive TURP or PVP
- •Randomization (after TURP or PVP)
- •Patients who have been diagnosed with OAB by the investigators
- •Patients who underwent catheter removal 5±2 days beforehand and will have more than an average of three urgency episodes per 24 hrs and more than an average of eight micturitions per 24 hrs in a row before Visit 3, as recorded in the voiding diary
- •Patients who will score more than 5 in questions 2, 4, and 7, which are on the storage symptoms in IPSS
- •Patients who will score more than 4 in question 3 and more than 5 in the OABSS
- •Patients who have not been treated with any medication for overactive bladder (OAB) symptoms 14 days before the randomization
排除标准
- •Screening
- •Patients who have been diagnosed with prostate cancer or bladder cancer and who have a present or resolved malignant disease in any pelvic organ
- •Patients who have neurological diseases that affect micturition and can cause neurogenic bladder disease such as multiple sclerosis, Parkinson's disease, severe cerebral arteriosclerosis, dementia, stroke, or myelitis
- •Patients who have had serious adverse events or are hypersensitive to anticholinergics
- •Patients who have a severe gastrointestinal obstruction disease such as toxin megacolon, ulcerative colitis, intestinal atonia, paralytic ileus, and gastric retention
- •Patients who have been diagnosed with severe myasthenia
- •Patients who have been diagnosed with narrow-angle glaucoma
- •Patients who have serious hepatic impairment (child class C)
- •Patients who are being treated with a CYP3A4 inhibitor (e.g., Ketoconazole)
- •Patients who have severe renal impairment or who are undergoing hemodialysis
- •Patients who have diabetic neuropathy
- •Patients who have a significant urinogenital disease such as UTI, interstitial cystitis, urothelial tumor, bladder stone, or urinary retention
- •Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- •Patients who have another medical or psychiatric condition that will make them inappropriate for participate in this study in the opinion of the investigators
- •Patients who have participated in other clinical trials within 30 days before the screening visit
- •Randomization
- •Patients who have been diagnosed with clinically significant bladder outlet obstruction by investigators
- •Patients whose PVR is greater than 100 mL
- •Patients who have been diagnosed with prostate cancer or bladder cancer and who have a present or resolved malignant disease in any pelvic organ
- •Patients who have neurological diseases that affect micturition and can cause neurogenic bladder disease such as multiple sclerosis, Parkinson's disease, severe cerebral arteriosclerosis, dementia, stroke, or myelitis
- •Patients who have had serious adverse events or are hypersensitive to anticholinergics
- •Patients who have a severe gastrointestinal obstruction disease such as toxin megacolon, ulcerative colitis, intestinal atonia, paralytic ileus, and gastric retention
- •Patients who have been diagnosed with severe myasthenia
- •Patients who have been diagnosed with narrow-angle glaucoma
- •Patients who have serious hepatic impairment (child class C)
- •Patients who are being treated with a CYP3A4 inhibitor (e.g., Ketoconazole)
- •Patients who have severe renal impairment or who are undergoing hemodialysis
- •Patients who experienced severe side effects after their operation
- •Patients who have diabetic neuropathy
- •Patients who have a significant urinogenital disease such as UTI, interstitial cystitis, urothelial tumor, bladder stone, or urinary retention
- •Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- •Patients who have another medical or psychiatric condition that will make them inappropriate for participate in this study in the opinion of the investigators
- •Patients who have participated in other clinical trials within 30 days before the screening visit
研究组 & 干预措施
Solifenacin group
Experimental
干预措施: Solifenacin Succinate (Drug)
Placebo group
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 2
时间窗: Baseline and at week 2
次要结局
- Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 4(Baseline and at week 4)
- Changes from baseline in IPSS voiding subscale score(Baseline, at week 2 and at week 4)
- Change from baseline in IPSS total score(Baseline, at week 2 and at week 4)
- Changes from baseline in IPSS QOL(Baseline, at week 2 and at week 4)
- Changes from baseline in OABSS total score(Baseline, at week 2 and at week 4)
- Maximum flow rate of the urine(Before treatment at week 2 and at week 4)
- Changes from baseline in IPSS storage subscale score(Baseline, at week 2 and at week 4)
- Changes from baseline in individual IPSS scores(Baseline, at week 2 and at week 4)
- Change from baseline in average number of micturitions per 24 hrs for three days as recorded in the voiding diary(Baseline, at week 2 and at week 4)
- Safety assessed by the incidence of adverse events, physical exam, and vital signs(For 4 weeks of the treatment)
- Urinal post voiding residual volume(Before treatment at week 2 and at week 4)
研究者
相似试验
已完成
4 期
A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive BladderUrinary Bladder, OveractiveNCT00699049KYU-SUNG LEE94
已完成
2 期
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive BladderUrologic DiseasesUrinary Bladder DiseasesUrological ManifestationsSigns and SymptomsUrinary Bladder, OveractiveNCT01340027Astellas Pharma Europe B.V.1,307
已完成
4 期
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical ProstatectomyUrinary IncontinenceNCT01371994Astellas Pharma Inc640
已完成
4 期
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic HyperplasiaBenign Prostatic HypertrophyOveractive BladderBenign Prostatic HyperplasiaNCT00771394Astellas Pharma Inc638
已完成
3 期
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive BladderUrinary Bladder OveractiveUrgency IncontinenceUrinary Bladder Diseases\Urologic DiseasesOveractive BladderNCT02045862Astellas Pharma Europe B.V.1,829